Centripetal Networks, Inc. v. Cisco Systems, Inc.
Pyrotechnics Management Inc v. XFX Pyrotechnics LLC

Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.

HEC Pharm Co., Ltd. and HEC Pharm USA Inc. (collectively, HEC) petition for rehearing of our prior decision in this case, 21 F.4th 1362 (Fed. Cir. 2022), in which we affirmed a final judgment of the United States District Court for the District of Delaware. The district court determined that claims 1–6 of U.S. Patent No. 9,187,405 are not invalid and that HEC infringes them. Because the ’405 patent fails to disclose the absence of a loading dose, the district court clearly erred in finding that the negative claim limitation “absent an immediately preceding loading dose” added during prosecution to overcome prior art satisfies the written description requirement of 35 U.S.C. § 112(a). We grant HEC’s petition for panel rehearing, vacate our prior decision, and reverse the district court’s judgment that Novartis’ claims are not invalid for inadequate written description.

Download Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc.


Registering your trademarks is one of the best long-term investments you can make in your business. Contact us today for more information.

Visit Gehrke & Associates, SC.


Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.


Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)